PODCAST EXAM Neurology: Volume 95, Number 6, August 11, 2020 Podcast Exam #477 - Mortality in patients with psychogenic nonepileptic seizures

About this Course

• Released: 08/12/2020
• Expires: 08/11/2023

MORTALITY IN PATIENTS WITH PSYCHOGENIC NONEPILEPTIC SEIZURES

LEARNING OBJECTIVES:

Upon completion of this podcast, listeners will become more familiar with the mortality risk of a diagnosis of psychogenic non-epileptic seizures.

CORE COMPETENCIES:

The podcast covers the following core competency:

• Medical Knowledge

AUTHOR DISCLOSURES:

Dr. David Lapides has served on the scientific advisory board of Biohaven; has served as a consultant for Board Vitals; has received commercial research support from Biogen; and has received foundation/society research support from the National Multiple Sclerosis Society Clinical Fellowship. Dr. Terence O’Brien has served on the medical advisory boards for Eisai, UCB, LivaNova, and Supernus; has received funding for travel or speaker honoraria from UCB Pharma and Eisai; has served on the editorial boards for Epilepsy and Behavior,  British Journal of Clinical Pharmacology, Epilepsia Open, and Epilepsia; has served as a medical monitor for Zynerba Pharmaceuticals; has received speaker fees from UCB and Eisai; has received commercial research support from UCB, Zynerba, Sanofi, Janssen-Cilag, and Eisai; has received governmental research support from NHMRC and NIH; and has received foundation/society research support from RMH Neuroscience Foundation. Dr. Jeffrey Ratliff has received speaker or travel honoraria from Teva and US WorldMeds LLC; serves as the Deputy Section Editor for Neurology Podcast; has served as a consultant for UCB Pharmaceuticals, US World Meds, LLC, Medscape, and Retrophin, Inc.; has served on speaker’s bureaus for Teva and US WorldMeds LLC; and has received an education research grant from the American Academy of Neurology. Dr. Nico Dosenbach has received funding for travel or speaker honoraria from NOUS Imaging Inc.; holds a patent for real-time monitoring and prediction of motion in MRI; is the co-founder and Director of NOUS Imaging Inc.; has received commercial research support form NOUS Imaging Inc.; has received governmental research support from NINDS and NIMH; has received foundation/society research support from Central Nervous System Recovery and Restoration (CNSRR), Kiwanis Neuroscience Research Foundation, and the Jacobs Foundation; holds founder stock in NOUS Imaging, Inc.; receives license fee payments from NOUS Imaging, Inc.; has receives royalty payments for patent holding.


The other participants report no disclosures.

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine. After evaluating a Neurology^® article featured in a podcast, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

CREDITS

The American Academy of Neurology designates that participants earn 0.5 AMA PRA Category 1 CME Credits™ for completion of each multiple-choice podcast exam. Physicians should only claim credit commensurate with the extent of their participation in the activity. CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.

DISCLOSURES

José G. Merino, MD, MPhil, FAAN: Funding for travel or speaker honoraria: I am or have been a member of several committees and programs of the AAN and I receive funding for travel related to these activities. I have also received travel support from the Mexican Academy of Neurology and from the Mexican Stroke Association for presentations at their annual meeting. Editorial Boards: 1. I am the Editor-in-Chief of Neurology and I receive salary support for the AAN to support my editorial activities through a contract between the journal and my employer, Georgetown University Hospital. 2. I was US Clinical Research Editor for The BMJ from 2012 to 2019 and received salary support from the journal through a contract between the journal and my employer, most recently (2016-2019) the University of Maryland School of Medicine. I was co-editor of Blogging stroke, A Stroke journal blog, until 2019. I did not receive compensation for this activity. Other activities: I was a stroke outcomes adjudicator (2009-2019) for the WHI study (NIH-funded). Stacey L. Clardy, MD, PhD, FAAN: Consulting/ Advisory Boards: Alexion, VielaBio, Genentech, Guidepoint, ExpertConnect, Clarion Healthcare Consulting. (*Majority Fees to U. Utah Development account). Editorial Boards: Section Editor, Neurology Podcast (July 2018-present) and Neurology Minute™ (March 2019-present). Research Support, Commercial Entities: Alexion, VielaBio. Site investigator: Alexion clinical trial for Eculizumab in Relapsing NMO patients (in extension). Research Support, Foundations and Societies: The Siegel Rare Neuroimmune Association (SRNA), the Barbara Gural Steinmetz Foundation, the Sumaira Foundation for NMO. Jeffrey B. Ratliff, MD: Funding for travel or speaker honoraria: (1) Teva, Honoraria (2) US World Meds LLC, Honoraria (3) Neurocrine, Honoraria. Editorial Boards: Neurology, Deputy Section Editor for Podcasts, 2019-Present. Consultancies: (1) US World Meds; Speakers' Bureaus: (1) Teva, (2) US WorldMeds LLC/Supernus, (3) Neurocrine. Research Support, Foundations and Societies: (1) American Academy of Neurology, Education Research Grant. AAN staff members editing the test (K. Aman Ramm) have no disclosures. CME Journal Editors who have reviewed the exam: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum.

COMMERCIAL SUPPORT

This CME program receives no commercial support.